
    
      This is a randomized, double-blind, double dummy, parallel group, multicenter 24 to 52 week
      variable length study to assess the efficacy and safety of budesonide, glycopyrronium, and
      formoterol fumarate metered dose inhaler (MDI) relative to budesonide and formoterol fumarate
      MDI and SymbicortÂ® pressurized MDI in adult and adolescent participants with inadequately
      controlled asthma. Approximately 2800 participants will be randomized globally.
    
  